EBV-associated post transplant lymphoproliferative disease (EBV-PTLD) is a life-threatening complication that may occur after hemopoietic SCT. We prospectively screened 80 children on a weekly basis using nested quantitative PCR to evaluate EBV genome copies. EBV viral load o1000 copies per 10 5 PBMC was observed in 63% of transplants, whereas it was between 1000 and 9999 copies per 10 5 PBMC in 13%, and between 10 000 and 19 999 in 10%, with no significant increase in percentage of CD20 þ lymphocytes. Viral load reached X20 000 copies per 10 5 PBMC in 14% of patients, and rituximab was administered to 75% of them. None of the patients except one developed a lymphoproliferative disease. Our study found that only 13% of unrelated donor HSCT recipients had a very high risk of EBV-PTLD defined as X20 000 geq per 10 5 PBMC associated with an increase in CD20 þ lymphocyte. We suggest that rituximab could be administered in the presence of very high levels of EBV-DNA viral load or in the presence of mid levels of EBV-DNA viral load associated with an increase in the percentage of CD20 þ lymphocytes. Through this approach, we significantly reduced the number of patients treated with rituximab, andIntroduction EBV-associated post transplant lymphoproliferative disease (EBV-PTLD) is a severe complication after allogeneic hemopoietic SCT (allo-HSCT), with an incidence varying from 0.45 to 29%, 1-3 mainly observed after unrelated allo-HSCT, T-cell-depleted allograft, antithymocyte globuline treatment and prolonged immunosuppression of GVHD. 4 Symptoms usually develop between 1 and 5 months after transplant, with a peak incidence during the third month post transplant. 5 They mainly consist of mononucleosis-like syndrome (early disease) or lymphoma-like picture with lymphadenopathy and mass lesions (monomorphic and polymorphic PTLD). Moreover, the clinical presentation may mimic allograft rejection, or may simulate GVHD. 6 Careful clinical monitoring and serial measurements of EBV DNA load in the peripheral blood (PB) or extracted from PBMC by means of PCR have proven to be helpful in identifying high-risk patients. At present there is no consensus on the cutoff of EBV-DNA copies for starting preemptive therapy with rituximab, 7 but the majority of authors suggest treating patients whose EBV viral load is equal to or higher than 1000 geq/ml or 200 copies per 10 5 PBMC. 6, 8 Polyclonal donor-derived T-cell lines specific for EBV proteins have been safely used to prevent EBV-PTLD after allogeneic HSCT and may also be effective in the treatment of established disease. 9 However, this technology is not widely available, and therefore rituximab may represent a life-saving treatment for this complication, even if its use has been associated with severe adverse events (for example, immediate reactions or severe pneumopathy) 10, 11 and delay in B-lymphocyte recovery that may last even for years. [12] [13] [14] The aim of this study was to evaluate whether measurements of both EBV-DNA viral load and percentage of CD20 þ lymphocytes could be used in the preemptive management of EBV-PTLD in children undergoing allogeneic HSCT.
Materials and methods
All consecutive children receiving allo-HSCT at the G Gaslini Children's Hospital, Genoa, Italy between June 2004 and June 2008 were eligible for this study. Data on demographics, underlying disease, and date and type of transplant were available in the institutional database for each eligible patient. For the purpose of the present study, an ad hoc database was prepared and included: type of transplant, categorized as (1) fully HLA compatible familiar, defined as matched related donor (MRD) and (2) all other types of donor (for example, matched unrelated, familiar not fully matched), defined as alternative donor (AD); 15 the EBV-DNA viral load, expressed as geq/ml of plasma or geq per 10 5 PBMC, and the percentage of CD20 þ lymphocytes; the date and number of rituximab administrations; the date of IgG synthesis recovery (defined as an IgG value 4500 mg per 100 ml in two determinations performed 1 month apart); the date of end of follow-up calculated from transplant to patient's death, or relapse of the underlying disease, or elective end of immunosuppression, whichever occurred first. Follow-up was stopped at 30 June 2008 for patients still in treatment at that date. In the case of patients receiving more than one transplant, each procedure was considered separately.
DNA for EBV viral load was extracted from 200 ml of PB with the QIAmp DNA Mini kit (Qiagen, Milano, Italy). The quantitative estimation of EBV-DNA viral load was evaluated by real-time PCR assay using Artus EBV RG PCR kit (Qiagen GmbH, Hilden, Germany) and expressed as geq/ml of whole blood per 100 000 PBMC (per 10 5 PBMC). EBV reactivation was defined as plasma EBV DNA 41000 copies per 10 5 PBMC. Low-level EBV reactivation was defined as a viral load of 1000-9999 copies per 10 5 PBMC; mid-level as 10 000-19 999 copies per 10 5 PBMC; high-level as X20 000 copies per 10 5 PBMC. The same categories were maintained when EBV-DNA copies were measured in whole blood, but clinical decisions, based on our previous experience, considered EBV-DNA copies detected per 10 5 PBMC. EBV-DNA viral load was monitored weekly in each patient. In the presence of an EBV viral load X10 000 copies per 10 5 PBMC, the test was repeated within 3-4 days and it was coupled with percentage of CD20 þ lymphocytes. Rituximab was administered at a dosage of 375 mg/m 2 when EBV-DNA viral load was X20 000 copies per 10 5 PBMC, or in the case of EBV-DNA viral load X10 000 copies per 10 5 PBMC associated with an increase in CD20 þ lymphocytes in two subsequent determinations, or in the case of evident clinical manifestations of monomorphic or polymorphic PTLD.
Categorical variables were described as absolute numbers and percentages. Continuous variables were described as median and range (minimum and maximum value). In the case of non-Gaussian distribution, which was tested using the Kolmogorov-Smirnov method, the interquartile (first and third) range (IQR) was reported as a measure of data dispersion. The statistical software InStat version 3.0a for Macintosh (GraphPad Software, San Diego, CA, USA) was used.
All the HSCT patients or their guardians had previously signed a consent form allowing the use of their data for clinical research purposes. The procedures we followed were in accordance with our institution's ethical standards and with the Declaration of Helsinki Principles. According to Italian guidelines, no other specific informed consent was required for the purposes of this study.
Results
During the study period, 80 children, 46 males and 34 females, median age 7 years (IQR 2.5-11) underwent 87 allogeneic HSCT procedures: 17 (19%) from an MRD and 70 (81%) from an AD ( Table 1 ). The median time of follow-up for each patient was 526 days (IQR 157-891). Table 2 summarizes the viral load according to type of HSCT donor and at different cutoffs of EBV-DNA copies. Overall, no EBV reactivations were observed in 55 (63%) procedures. Low-level EBV reactivation was observed in 11 procedures (13%), 1 MRD and 10 AD-HSCT. In nine others (10%), all from AD, viral load was between 10 000 and 19 999 copies per 10 5 PBMC. None of them developed further increases in viral load or any significant changes in percentage of CD20 þ lymphocytes, clinical signs suggestive of EBV disease and PTLD. Among the MRD-HSCT, there were no cases of high-level EBV reactivation. On the contrary, high-level EBV reactivation was observed in 12 AD-HSCT procedures (14% of all procedures, 17% of AD-HSCT) after a median of 40 (range 19-97) days from transplant. In two cases high-level EBV was not associated with an increase in the percentage of CD20 þ lymphocytes but these patients presented graft rejection, and relapse of the underlying disease, respectively. In another case the measurement of CD20 þ lymphocytes showed a decrease in two subsequent samples. All these three cases did not receive rituximab. In the remaining nine cases, high-level EBV reactivation was associated with a rapid increase in the percentage of CD20 þ lymphocytes. Therefore, all patients received preemptive therapy with rituximab associated with a reduction of immunosuppressive therapies. Eight of them received one or two doses of preemptive therapy with rituximab and did not develop PTLD. Among these eight cases, no recurrence of IgG production was observed in four cases over a follow-up of 41, 156, 717 and 1356 days after the last infusion, respectively. In the other four patients, recovery of IgG synthesis was observed 350, 364, 369, and 533 days after the last infusion, respectively. Only one of the nine patients with high-level EBV reactivation developed full-blown PTLD (1.1% of all procedures, 1.4% of AD-HSCT) successfully treated with chemotherapy, multiple doses of rituximab and cellular therapy. 16 If we had evaluated EBV viral load as geq/ml, maintaining the cutoff value of X20 000 geq/ml, the number of patients who would have been candidates for rituximab preemptive therapy was 1 MRD and 29 AD-HSCT recipients ( Table 2) .
Discussion
The present study suggests that an EBV viral load cutoff X20 000 per 10 5 PBMC or X10 000 per 10 5 associated with a rise in CD20 þ lymphocytes could represent a reliable diagnostic approach to identify pediatric allo-HSCT recipients eligible for rituximab preemptive therapy. As reported in a recent guideline about the management of viral infections after HSCT, 17 there is no consensus on the optimal method to assess EBV-DNA load, even if the majority of centers quantify EBV load in whole blood or plasma. In our single centre experience we evaluated EBV DNA in whole blood and the EBV viral load was referred to 10 5 PBMC. This simple and reproducible method allowed us to avoid manipulating cellular samples that could cause loss of cells, and therefore provided us with a more accurate estimation of viral load.
In published data there is a wide variability on cutoff levels of EBV DNA used to start preemptive therapy for EBV-PTLD in HSCT recipients, thus confirming that the threshold of EBV load for diagnosis of PTLD should be defined on the basis of local data. 17 Some authors using molecular quantification of EBV-DNA viral load extracted from 100 ml of blood indicated a cutoff of 1000 geq/ml to identify patients eligible for preemptive therapy. 4, 18, 19 When EBV DNA was measured in 10 5 PBMC, the proposed cutoff ranged from X300 20 to 4500 21 to 41000 copies per 10 5 PBMC. 22 On the contrary, Ahmad et al. 23 and Aalto et al. 24 suggested a higher cutoff EBV-DNA viral load 440 000 and X50 000 geq/ml, as predictive of PTLD. Our results are in agreement with the use of a higher cutoff (both as geq/ml or copies per 10 5 PBMC) for the identification of patients needing preemptive therapy for EBV-PTLD. In fact, in our cohort, a combination of careful clinical monitoring, high-level cutoff of EBV-DNA viral load and monitoring of CD20 þ lymphocyte in the presence of mid-level EBV reactivation allowed for a significant reduction in the number of patients who received preemptive rituximab (9 of 87, 10%), compared with what would append using other approaches with a standard cutoff 41000 geq/ml (43 of 87, 49%). Considering the risk of severe adverse events associated with rituximab administration in post transplant patients, [10] [11] [12] [13] [14] such as allergic reactions and long-lasting hypogammaglobulinemia, the adoption of our strategy could be helpful for a more precise and refined treatment of EBV-PTLD. 
